Sopharma AD-Sofia (FRA:3JR) Ending Cash Position: €22 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3JR Sopharma AD-Sofia FRA:3JR
67 GF Score
Price €1.86
GF Value €2.94
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Ending Cash Position?

Sopharma AD-Sofia FRA:3JR +6.29% 67 Ending Cash Position is €22 Mil as of Mar. 2026. GuruFocus rates FRA:3JR with a GF Score™ of 67/100 and a GF Value™ of €2.94 (Possible Value Trap). The stock has 4 warning signs investors should review.

Sopharma AD-Sofia's Ending Cash Position for the quarter that ended in Mar. 2026 was €22 Mil.

Sopharma AD-Sofia's quarterly Ending Cash Position increased from Sep. 2025 (€17 Mil) to Dec. 2025 (€37 Mil) but then declined from Dec. 2025 (€37 Mil) to Mar. 2026 (€22 Mil).

Sopharma AD-Sofia's annual Ending Cash Position declined from Dec. 2023 (€66 Mil) to Dec. 2024 (€18 Mil) but then increased from Dec. 2024 (€18 Mil) to Dec. 2025 (€37 Mil).

Sopharma AD-Sofia Ending Cash Position Related Terms

Sopharma AD-Sofia Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Ending Cash Position Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.22 10.06 65.57 18.15 36.50

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.64 17.57 16.63 36.50 22.14
FRA:3JR
67GF Score
Sopharma AD-Sofia FRA:3JR
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sopharma AD-Sofia's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=18.147+18.357
=37

Sopharma AD-Sofia's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=36.645+-14.504
=22

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €22 Mil mean?
Sopharma AD-Sofia (FRA:3JR) has a Ending Cash Position of €22 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Ending Cash Position too high?
Sopharma AD-Sofia's current Ending Cash Position is €22 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Ending Cash Position compare to MCK and COR?
Sopharma AD-Sofia's Ending Cash Position of €22 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Distribution company?
A good Ending Cash Position depends on the Medical Distribution industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Ending Cash Position is €22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (FRA:3JR) is currently considered Possible Value Trap. The stock's GF Value™ is €2.94, compared to a current price of €1.86 — trading 36.7% below its estimated fair value. The current Ending Cash Position is €22 Mil. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current Ending Cash Position is €22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of €1.86 is trading 36.7% below its estimated GF Value™ of €2.94. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for FRA:3JR:

  • Ending Cash Position: €22 Mil
  • GF Value™: €2.94 vs. price of €1.86 (36.7% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges SPH:PolandSFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score

Get the complete analysis for FRA:3JR

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.86
Price
€2.94
GF Value